Canadian Cancer Trials Group Bulletins


Investigational New Drug (IND) Program Recognition Awards

The Canadian Cancer Trials Group is very pleased to announce that two inaugural Investigational New Drug (IND) Program awards named after Dr. Elizabeth Eisenhauer, past Director of the IND Program, were presented at the Canadian Cancer Trials Group's recent Annual Spring Meeting of Participants.

The Elizabeth Eisenhauer Early Drug Development Team Award is presented annually to a non-MD team of clinical research associates, nurses, pharmacists and others who participated in any Canadian Cancer Trials Group IND clinical trial(s). Teams are reviewed based on speed of trial activation, number of times provincial applicant (if applicable), quality of data, accrual, and overall centre and trial metrics.

The selected team will receive a glass award and each member of the team receives a certificate of recognition to be presented at the IND Open Meeting.

This year's team award was presented to the IND.205 Team at the British Columbia Cancer Agency (BCCA) Vancouver Cancer Centre -- Ms. Rongrong Karim, Mr. Shane Brown, and Mr. Wilfred Hui.

Ms. Karim graduated from the University of Manitoba, followed by the Hospital Pharmacy Residency in Vancouver. She has worked as a Clinical Trials Pharmacist at the Vancouver Cancer Centre since 2004.

Mr. Shane Brown is a clinical trials nurse who graduated from University of Victoria. He worked in the Burns and Plastics unit and in Forensic Psychiatry at the Vancouver General Hospital before moving to the ambulatory care unit at BCCA in 2008. He has been a member of the Clinical Trials Unit in Vancouver since 2010.

Mr. Wilfred Hui received a Bachelor's Degree from the University of British Columbia and a Diploma in Health Information Management from Douglas College. He has worked as a Clinical Trials Data Coordinator at BCCA Vancouver Cancer Centre since 2011.

IND.205 Team at the British Columbia Cancer Agency (BCCA) Vancouver Cancer Centre

The Elizabeth Eisenhauer Young Investigator Award is presented annually to any MD, fellow, or PhD, within 3 years of certification / first faculty appointment, or current fellow who has either spent time at Canadian Cancer Trials Group's Central Office, worked on projects with the Investigational New Drug Program or who has contributed significantly to the conduct of an IND trial at a centre.

The selected investigator will receive a glass award, a certificate of recognition and an opportunity to present his/her work at the IND Open Meeting at Spring Meeting.

This year's recipient is Dr. Jose Monzon, a medical oncologist at the Tom Baker Cancer Centre in Calgary, Alberta. Dr. Monzon completed his postgraduate medical oncology residency training at the University of British Columbia and translational fellowship training at the Canadian Cancer Trials Group. He has also completed a PhD focusing on melanoma genetics at the University of Toronto. His current research interests include pharmacogenomics and early phase clinical trials in cutaneous and gastrointestinal malignancies.

Jose Monzon

Congratulations to this year's recipients!!